Cancer outcomes and biological mechanisms among patients with type 2 diabetes mellitus using glucagon-like peptide-1 receptor agonists: a systematic review and meta-analysis - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Impact of Glucagon-Like Peptide-1 Receptor Agonists on Cancer Outcomes and Biological Mechanisms in Type 2 Diabetes Mellitus Patients: A Systematic Review and Meta-Analysis

  • By

  • Ejike Daniel Eze

  • Leopold Ntakirutimana

  • Swase Dominic Terkimbi

  • Muluken Walle

  • Abdullahi Hussein Umar

  • Diresibachew Haile Wondimu

  • Makinde Vincent Olubiyi

  • Onyinye Cynthia Okeke

  • Olufunke Onaadepo

  • Jimoh Abdulazeez

  • David Chibuike Ikwuka

  • Elemi John Ani

  • Abdullateef Isiaka Alagbonsi

  • July 14, 2026

Share

  • 1

    GLP-1 receptor agonists (GLP-1RAs) are associated with a significant reduction in overall cancer risk among type 2 diabetes mellitus (T2DM) patients.

  • 2

    Cancer-specific analyses revealed significant reductions in pancreatic, colorectal, endometrial, ovarian, hepatocellular, esophageal, and gastric cancers.

  • 3

    No significant associations were found between GLP-1RAs and thyroid, breast, kidney, or prostate cancers.

  • 4

    Mechanistic evidence regarding GLP-1RAs' influence on tumor biology is limited and primarily indirect.

  • 5

    The study highlights substantial heterogeneity and reliance on observational evidence, necessitating cautious interpretation of findings.

Original Source(s)

Cancer outcomes and biological mechanisms among patients with type 2 diabetes mellitus using glucagon-like peptide-1 receptor agonists: a systematic review and meta-analysis

  • by Ejike Daniel Eze, Leopold Ntakirutimana, Swase Dominic Terkimbi, Muluken Walle, Abdullahi Hussein Umar, Diresibachew Haile Wondimu, Makinde Vincent Olubiyi, Onyinye Cynthia Okeke, Olufunke Onaadepo, Jimoh Abdulazeez, David Chibuike Ikwuka, Elemi John Ani, Abdullateef Isiaka Alagbonsi

  • July 14, 2026

Related Content

Genetic Testing in Retinoblastoma: New Applications

Liquid biopsy and molecular profiling are expanding the diagnostic and prognostic role of genetic testing in retinoblastoma.

Correction: Primary cutaneous adenoid cystic carcinoma of the right forearm: a case report and dermoscopic features

This Week’s CGT News: Bristol Myers Ends Cellares Manufacturing Agreement

A first-in-human study reduces stem-cell collection and manufacturing times, Bristol Myers ends its Breyanzi agreement with Cellares, and two approaches strengthen CAR T-cell activity against solid tumors

  • August 31, 2026

  • 5 min